UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

July 20, 2023

Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.

July 20, 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

July 13, 2023

Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.

July 13, 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

July 13, 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

July 13, 2023

Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.

July 06, 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

July 06, 2023

Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.

July 06, 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

July 06, 2023

Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.

June 29, 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

June 29, 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

June 29, 2023

Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.

June 29, 2023

Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.

June 21, 2023

Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.

May 19, 2023

Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.

May 01, 2023

Aaron Lisberg, MD, discusses ongoing and future efforts to expand effective treatment options for patients with osimertinib-resistant, EGFR-mutant non–small cell lung cancer.

April 24, 2023

Edward B. Garon, MD, MS, discusses challenges associated with the incorporation of immunotherapy into the treatment paradigm for EGFR-mutant non–small cell lung cancer.

April 03, 2023

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.

March 29, 2023

As the development of systemic treatments for metastatic colorectal cancer move toward precision therapy, guidelines have adjusted to integrate decisions based on molecular drivers.